On November 7, GSK announced that the Phase III open-label, randomized, head-to-head superiority DREAMM-3 trial failed to meet the primary endpoint of progression-free survival (PFS).
On November 3, Affimed announced that it will present an update on the ongoing Phase I/II clinical trial at the ASH Congress. The study was
AB-836, a next-generation oral hepatitis B virus (HBV) capsid inhibitor (class II capsid inhibitor) that Arbutus Biopharma is developing for the treatment of chronic hepatitis
In July of this year, DeepMind, which developed AlphaFold, announced that it had increased the amount of predicted protein structure data from 1 million to
Antibody-drug conjugate (ADC) therapy has developed rapidly in recent decades. Currently, 14 products have been approved worldwide and more than 140 ADCs are in clinical
On November 4, German Chancellor Schultz announced a new agreement with the Chinese government. The Chinese government approved Germany’s BioNTech’s covid-19 vaccine for use by
On November 3, the Institute of Clinical and Economic Review (ICER) announced that, after a cost-benefit analysis, it assessed the price ceiling of Roctavian (valoctocogene
Foreword The mucin (MUC) family is a group of highly glycosylated macromolecules that are abundantly expressed in mammalian epithelial cells. Mucins contribute to the formation
Ascendis Pharma announced that the FDA has accepted and granted Priority Review status for TransCon PTH for the treatment of adult patients with hypoparathyroidism, with
On November 1, Rhythm Pharmaceuticals announced that its MC4R agonist setmelanotide was granted Breakthrough Therapy Designation by the FDA for the treatment of hypothalamic obesity.
Foreword Chimeric antigen receptor (CARs)-based T-cell therapy has shown great success against blood cancers; however, potential lethal toxicity (eg, cytokine release syndrome) and high cost
On October 31, Actinium Pharmaceuticals announced that the pivotal Phase III SIERRA study of its CD45 monoclonal antibody Iomab-B (apamistamab) in patients with relapsed or
